Low-Dose Aspirin at GCA Diagnosis May Reduce Cardiovascular Events but Increase Bleeding Risk

Low-dose aspirin initiated at the time of giant cell arteritis (GCA) diagnosis is associated with a reduced risk of major cardiovascular events within one year, but also with an increased risk of major hemorrhage, according to recent findings.

This association was identified in research examining outcomes among patients newly diagnosed with GCA, a form of vasculitis involving inflammation of large arteries. The study found that initiating low-dose aspirin at diagnosis correlated with a lower probability of experiencing major adverse cardiovascular events, such as heart attack, stroke, or cardiovascular death, over the following 12 months.

However, the same analysis revealed a trade-off: patients who received low-dose aspirin at GCA diagnosis also faced a higher likelihood of major bleeding events compared to those who did not. These bleeding complications included gastrointestinal hemorrhage and other clinically significant hemorrhages requiring medical intervention.

The cardiovascular benefit appeared more pronounced in certain subgroups, particularly women and individuals with diabetes, based on subgroup analyses within the study. Researchers noted that these populations experienced a stronger association between aspirin use and reduced cardiovascular risk.

Giant cell arteritis primarily affects adults over the age of 50 and is characterized by inflammation of the temporal arteries and other large vessels. Common symptoms include new-onset headaches, scalp tenderness, jaw pain during chewing, and visual disturbances. If untreated, GCA can lead to serious complications such as permanent vision loss or aortic aneurysm.

Current standard treatment for GCA involves high-dose glucocorticoids, such as prednisone, to suppress inflammation. Low-dose aspirin is not universally prescribed as part of initial management, though its potential role in mitigating cardiovascular risk has been explored in observational studies.

The findings align with broader research on aspirin’s effects in cardiovascular prevention, where low-dose therapy is known to reduce clot formation but carries an inherent bleeding risk. In the context of GCA, where vascular inflammation may contribute to thrombotic events, aspirin’s antiplatelet properties could offer protection against cardiovascular complications.

Experts caution that while the observed associations are meaningful, they do not establish causation. The study design was observational, meaning it identified patterns in patient outcomes but cannot confirm that aspirin directly caused the reduction in cardiovascular events or the increase in bleeding risk. Randomized controlled trials would be needed to determine whether initiating low-dose aspirin at GCA diagnosis provides a net clinical benefit.

Clinical decision-making regarding aspirin use in GCA should consider individual patient factors, including age, comorbidities, bleeding history, and cardiovascular risk profile. Physicians are advised to weigh the potential protective effects against the increased likelihood of hemorrhage when discussing treatment options.

As of now, major guideline bodies have not issued specific recommendations endorsing routine low-dose aspirin use at GCA diagnosis. Ongoing research continues to evaluate the balance of risks and benefits, particularly in high-risk subgroups where the signal of cardiovascular protection appears strongest.